Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 140

Sort by

Sort Order Select

Journal Articles

DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1

Giorgia Chiodin, Dylan Tatterton, Patrick J Duriez, Ayse Ertay, Philip J Rock, Benjamin Sale, Stuart Lanham, Luis Del Rio, Carl Figdor, Richard Burack, Freda K Stevenson, Francesco Forconi

Blood (2022) 140 (Supplement 1): 6460–6461.

https://doi.org/10.1182/blood-2022-169647

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

EMT-like Activation in CLL Provides Novel Therapeutic Target

Charlott Repschlaeger, Mariette Odabashian, Filomena Spada, Zamzam Almutairi, John G. Gribben, Francesco Forconi, Emre Sayan, Alexessander Couto Alves, Charline Giroud, Oleg Fedorov, Marina Kriajevskaia, Sergey Krysov

Blood (2022) 140 (Supplement 1): 12375–12376.

https://doi.org/10.1182/blood-2022-162696

Published: 2022

Journal Articles

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment

Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Lindsay D. Smith, Francesco Forconi, Bauke V. Schomakers, Michel van Weeghel, Dean J. Bryant, Jaco A. C. van Bruggen, Fleur S. Peters, Jeffrey C. Rathmell, Gerritje J. W. van der Windt, Arnon P. Kater, Graham Packham, Eric Eldering

Blood (2022) 140 (6): 630–643.

https://doi.org/10.1182/blood.2021013990

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance

Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Francesco Forconi, Bauke V Schomakers, Michel van Weeghel, Dean Bryant, Jaco A. C. Van Bruggen, Fleur Peters, Gerritje J. W. van der Windt, Arnon P. Kater, Graham Packham, Eric Eldering

Blood (2021) 138 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2021-150236

Published: 2021

Journal Articles

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 642.

https://doi.org/10.1182/blood-2021-152319

Published: 2021

Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2021-152167

Published: 2021

Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt

Blood (2021) 138 (Supplement 1): 2411.

https://doi.org/10.1182/blood-2021-144836

Published: 2021

Journal Articles

Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior

Blood (2021) 138 (17): 1570–1582.

https://doi.org/10.1182/blood.2021012052

Published: 2021

Includes: Supplemental data

Journal Articles

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Blood (2021) 138 (10): 827–835.

https://doi.org/10.1182/blood.2020010029

Published: 2021

Journal Articles

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg, Danique J. C. Bax, Stacey M. Fernandes, Jannie Borst, Constantine Tam, Francesco Forconi, Giorgia Chiodin, Jennifer R. Brown, Julie Dubois, Arnon P. Kater, Eric Eldering

Blood (2020) 136 (25): 2918–2926.

https://doi.org/10.1182/blood.2019004326

Published: 2020

Includes: Supplemental data

Journal Articles

Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia

Zhenghao Chen, Gaspard Cretenet, Beatriz Valle-Argos, Francesco Forconi, MD PhD FRCPath, Arnon P. Kater, MDPhD, Graham Packham, PhD, Eric Eldering, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-142839

Published: 2020

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Blood (2020) 135 (21): 1859–1869.

https://doi.org/10.1182/blood.2019003453

Published: 2020

Includes: Supplemental data

Journal Articles

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Mariette Odabashian, Emanuela Carlotti, Shamzah Araf, Jessica Okosun, Filomena Spada, John G. Gribben, Francesco Forconi, Freda K. Stevenson, Mariarita Calaminici, Sergey Krysov

Blood (2020) 135 (11): 834–844.

https://doi.org/10.1182/blood.2019002279

Published: 2020

Includes: Supplemental data

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Zhenghao Chen, Gaspard Cretenet, Hanneke ter Burg, Gabriela Andrejeva, Jeffrey C Rathmell, Francesco Forconi, MD DM, PhD FRCPath, Gerritje J. W. van der Windt, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 479.

https://doi.org/10.1182/blood-2019-123005

Published: 2019

Journal Articles

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

Giorgia Chiodin, Joel Allen, Philip J Rock, Enrica Antonia Martino, MD, Beatriz Valle Argos, PhD, Graham Packham, PhD, Patrick Duriez, PhD, Teunis Geijtenbeek, PhD, Carl Figdor, PhD, Richard Burack, MD PhD, Max Crispin, PhD, Freda K Stevenson, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2019) 134 (Supplement_1): 1505.

https://doi.org/10.1182/blood-2019-127159

Published: 2019

Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Blood (2019) 134 (Supplement_1): 1752.

https://doi.org/10.1182/blood-2019-128899

Published: 2019

NARROW

DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

EMT-like Activation in CLL Provides Novel Therapeutic Target

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment

Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior

Exploring the pathways to chronic lymphocytic leukemia

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only